Nadia Howlader
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nadia Howlader has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Angela B. Mariotto
National Cancer Institute 1 Division of Cancer Control and Population Sciences Bethesda, Maryland
46 shared publications - Jennifer L. Stevens
Information Management Services, Inc , Calverton, MD
27 shared publications - Karen Mittu
Information Management Services Calverton Maryland USA
27 shared publications - Ron A. Dewar
Cancer Care Program, Nova Scotia Health Authority, Nova Scotia, Canada
27 shared publications - Theresa P. Devasia
National Cancer Institute 1 Division of Cancer Control and Population Sciences Bethesda, Maryland
27 shared publications - Kathleen A. Cronin
Division of Cancer Control and Population Sciences, National Cancer Institute , Rockville, MD
20 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018
Supplementary Figure 1: Trends in Mortality by Leukemia Subtypes and Race Ethnicity. Total US 1992-2018. Results are shown for mortality trends for CML (panel A), ALL (panel B), and CLL (panel C), 1992-2018. For each panel, we show age-adjusted mortality rates by five mutually exclusive race-ethnicity categories: non-Hispanic White, non-Hispanic Black, non-Hispanic Asian Pacific Islander, non-Hispanic American Indian/Alaskan Natives, and Hispanic.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018
Supplementary Figure 1: Trends in Mortality by Leukemia Subtypes and Race Ethnicity. Total US 1992-2018. Results are shown for mortality trends for CML (panel A), ALL (panel B), and CLL (panel C), 1992-2018. For each panel, we show age-adjusted mortality rates by five mutually exclusive race-ethnicity categories: non-Hispanic White, non-Hispanic Black, non-Hispanic Asian Pacific Islander, non-Hispanic American Indian/Alaskan Natives, and Hispanic.
- Open Access
Urban–rural disparities in lung cancer incidence and mortality patterns in Black and White populations
Background: Lung cancer mortality trends among Black and White populations and urban compared to rural populations are critical for assessing disparities in cancer outcomes. Methods: This serial cross‐sectional study used US national death certificate data from the National Center for Health Statistics and data from the National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program. The study analyzed lung cancer incidence (2001–2021) and mortality (1990–2021) trends by race, sex, and urban–rural status. Age‐adjusted incidence and mortality rates and average annual percent changes (AAPCs) were estimated. Results: Since 1990, lung cancer death rates have declined faster for Black men, which has reduced the gap with White men, but White women have consistently had higher rates than Black women. Rural areas showed higher incidence and mortality rates compared to urban areas. During 2013–2021, incidence rates declined similarly among urban and rural Black men (AAPC, −3.4 and −4.3, respectively) and White men (AAPC, −3.6 and −2.7, respectively). However, mortality rates decreased faster for urban Black men than for rural Black men (AAPC, −5.4 vs. −4.5) and for urban White men than for rural White men (AAPC, −4.8 vs. −4.0). Incidence and mortality rates declined faster for urban Black and White women than for their rural counterparts. Conclusions: Although the disparity in lung cancer death rates between Black and White men has narrowed, significant disparities persist between urban and rural populations. The more rapid decline in mortality rates in urban areas suggests that recent treatment advancements may be less accessible to rural populations.
Open AccessUrban–rural disparities in lung cancer incidence and mortality patterns in Black and White populations
Background: Lung cancer mortality trends among Black and White populations and urban compared to rural populations are critical for assessing disparities in cancer outcomes. Methods: This serial cross‐sectional study used US national death certificate data from the National Center for Health Statistics and data from the National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program. The study analyzed lung cancer incidence (2001–2021) and mortality (1990–2021) trends by race, sex, and urban–rural status. Age‐adjusted incidence and mortality rates and average annual percent changes (AAPCs) were estimated. Results: Since 1990, lung cancer death rates have declined faster for Black men, which has reduced the gap with White men, but White women have consistently had higher rates than Black women. Rural areas showed higher incidence and mortality rates compared to urban areas. During 2013–2021, incidence rates declined similarly among urban and rural Black men (AAPC, −3.4 and −4.3, respectively) and White men (AAPC, −3.6 and −2.7, respectively). However, mortality rates decreased faster for urban Black men than for rural Black men (AAPC, −5.4 vs. −4.5) and for urban White men than for rural White men (AAPC, −4.8 vs. −4.0). Incidence and mortality rates declined faster for urban Black and White women than for their rural counterparts. Conclusions: Although the disparity in lung cancer death rates between Black and White men has narrowed, significant disparities persist between urban and rural populations. The more rapid decline in mortality rates in urban areas suggests that recent treatment advancements may be less accessible to rural populations.
- Open Access
- 25 October 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (5) , 1064-1068
Assessing the effect of the COVID-19 pandemic on 1-year cancer survival in the United States
The COVID-19 pandemic had a substantial impact on health-care delivery. We used the Surveillance, Epidemiology, and End Results (SEER) data to assess changes in 1-year relative survival and competing risk probabilities of cancer and non-cancer death for patients diagnosed in 2018 Q2 (pre-pandemic) and 2020 Q2 (pandemic). For all cancer sites combined, 1-year relative survival declined from 82.3% in 2018 Q2 to 77.5% in 2020 Q2, with the steepest declines seen in stomach, leukemia, and liver cancers. However, survival improved nearing pre-pandemic levels during 2020 Q3. Competing risk survival measures revealed that the decline in 1-year survival was driven by increases in both the probability of dying of cancer (rising from 15.4% to 19.2%) and of other causes, including COVID-19 (rising from 3.8% to 5.2%). The pandemic led to substantial declines in survival and increased mortality from both cancer and other causes for patients diagnosed in 2020 Q2.
- 25 October 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (5) , 1064-1068
Open AccessAssessing the effect of the COVID-19 pandemic on 1-year cancer survival in the United States
The COVID-19 pandemic had a substantial impact on health-care delivery. We used the Surveillance, Epidemiology, and End Results (SEER) data to assess changes in 1-year relative survival and competing risk probabilities of cancer and non-cancer death for patients diagnosed in 2018 Q2 (pre-pandemic) and 2020 Q2 (pandemic). For all cancer sites combined, 1-year relative survival declined from 82.3% in 2018 Q2 to 77.5% in 2020 Q2, with the steepest declines seen in stomach, leukemia, and liver cancers. However, survival improved nearing pre-pandemic levels during 2020 Q3. Competing risk survival measures revealed that the decline in 1-year survival was driven by increases in both the probability of dying of cancer (rising from 15.4% to 19.2%) and of other causes, including COVID-19 (rising from 3.8% to 5.2%). The pandemic led to substantial declines in survival and increased mortality from both cancer and other causes for patients diagnosed in 2020 Q2.
- Open Access
- 24 September 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (3) , 507-510
Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline
The COVID-19 pandemic led to substantial declines in cancer incidence rates in 2020, likely because of disruptions in screening and diagnostic services. This study aimed to assess the impact of the pandemic on cancer incidence rates in the United States using 2021 incidence data from the Surveillance, Epidemiology, and End Results program. The analysis compared observed 2021 cancer incidence rates with expected prepandemic trends, evaluating changes by individual cancer site and stage. Although incidence overall and in many cancer sites the rates were close to prepandemic levels, they did not exhibit a recovery that incorporated the delayed diagnoses from 2020. There were exceptions, however, such as metastatic breast cancer, which showed significantly higher observed rates than expected (rate ratio = 1.09, 95% confidence interval = 1.04 to 1.13). Ongoing monitoring and targeted interventions are needed to address the long-term consequences of the COVID-19 pandemic on cancer care and outcomes.
- 24 September 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (3) , 507-510
Open AccessImpact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline
The COVID-19 pandemic led to substantial declines in cancer incidence rates in 2020, likely because of disruptions in screening and diagnostic services. This study aimed to assess the impact of the pandemic on cancer incidence rates in the United States using 2021 incidence data from the Surveillance, Epidemiology, and End Results program. The analysis compared observed 2021 cancer incidence rates with expected prepandemic trends, evaluating changes by individual cancer site and stage. Although incidence overall and in many cancer sites the rates were close to prepandemic levels, they did not exhibit a recovery that incorporated the delayed diagnoses from 2020. There were exceptions, however, such as metastatic breast cancer, which showed significantly higher observed rates than expected (rate ratio = 1.09, 95% confidence interval = 1.04 to 1.13). Ongoing monitoring and targeted interventions are needed to address the long-term consequences of the COVID-19 pandemic on cancer care and outcomes.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from The Impact of Improved Treatments on Survival of Adult US Leukemia Patients: 1990 - 2018
Supplementary Figure 1: Trends in Mortality by Leukemia Subtypes and Race Ethnicity. Total US 1992-2018. Results are shown for mortality trends for CML (panel A), ALL (panel B), and CLL (panel C), 1992-2018. For each panel, we show age-adjusted mortality rates by five mutually exclusive race-ethnicity categories: non-Hispanic White, non-Hispanic Black, non-Hispanic Asian Pacific Islander, non-Hispanic American Indian/Alaskan Natives, and Hispanic.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from The Impact of Improved Treatments on Survival of Adult US Leukemia Patients: 1990 - 2018
Supplementary Figure 1: Trends in Mortality by Leukemia Subtypes and Race Ethnicity. Total US 1992-2018. Results are shown for mortality trends for CML (panel A), ALL (panel B), and CLL (panel C), 1992-2018. For each panel, we show age-adjusted mortality rates by five mutually exclusive race-ethnicity categories: non-Hispanic White, non-Hispanic Black, non-Hispanic Asian Pacific Islander, non-Hispanic American Indian/Alaskan Natives, and Hispanic.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from The Impact of Improved Treatments on Survival of Adult US Leukemia Patients: 1990 - 2018
Introduction: Molecularly targeted therapies such as tyrosine kinase inhibitors (TKIs) are effective treatments for BCR-ABL-bearing leukemias. We evaluated the impact of TKIs on historical chronic myeloid leukemia (CML) mortality trends compared to acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL). Methods: Since mortality trends reflect combined effects of leukemia incidence and survival, we also evaluated the contribution of incidence and survival trends to mortality trends by subtypes. We used data from 13 US SEER registries (1992-2017) among US adults. We utilized histology codes to identify cases of CML, ALL, and CLL and death certificate data to calculate mortality. We used Joinpoint to characterize incidence (1992-2017) and mortality (1992-2018) trends by subtype and diagnosis year. Results: For CML, mortality rates started declining in 1998 at an average rate of 12% annually. Imatinib was approved by the FDA for treating CML and ALL in 2001, leading to clear benefits for CML patients. Five-year CML survival increased dramatically over time, especially between 1996-2011, 2.3% per year on average. ALL incidence increased 1.5% annually from 1992-2017. ALL mortality decreased 0.6% annually during 1992-2012 and then stopped declining. CLL incidence fluctuated during 1992–2017 while mortality decreased 1.1% annually during 1992-2011 and at a faster rate of 3.6% per year from 2011. Five-year survival increased 0.7% per year on average during 1992-2016. Conclusions: Survival benefit from TKIs and other novel therapies for treating leukemia subtypes has been demonstrated in clinical trials. Impact: Our study highlights the impact of molecularly targeted therapies at the population level.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Impact of Improved Treatments on Survival of Adult US Leukemia Patients: 1990 - 2018
Introduction: Molecularly targeted therapies such as tyrosine kinase inhibitors (TKIs) are effective treatments for BCR-ABL-bearing leukemias. We evaluated the impact of TKIs on historical chronic myeloid leukemia (CML) mortality trends compared to acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL). Methods: Since mortality trends reflect combined effects of leukemia incidence and survival, we also evaluated the contribution of incidence and survival trends to mortality trends by subtypes. We used data from 13 US SEER registries (1992-2017) among US adults. We utilized histology codes to identify cases of CML, ALL, and CLL and death certificate data to calculate mortality. We used Joinpoint to characterize incidence (1992-2017) and mortality (1992-2018) trends by subtype and diagnosis year. Results: For CML, mortality rates started declining in 1998 at an average rate of 12% annually. Imatinib was approved by the FDA for treating CML and ALL in 2001, leading to clear benefits for CML patients. Five-year CML survival increased dramatically over time, especially between 1996-2011, 2.3% per year on average. ALL incidence increased 1.5% annually from 1992-2017. ALL mortality decreased 0.6% annually during 1992-2012 and then stopped declining. CLL incidence fluctuated during 1992–2017 while mortality decreased 1.1% annually during 1992-2011 and at a faster rate of 3.6% per year from 2011. Five-year survival increased 0.7% per year on average during 1992-2016. Conclusions: Survival benefit from TKIs and other novel therapies for treating leukemia subtypes has been demonstrated in clinical trials. Impact: Our study highlights the impact of molecularly targeted therapies at the population level.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from The Impact of Improved Treatments on Survival of Adult US Leukemia Patients: 1990 - 2018
Supplementary Figure 1: Trends in Mortality by Leukemia Subtypes and Race Ethnicity. Total US 1992-2018. Results are shown for mortality trends for CML (panel A), ALL (panel B), and CLL (panel C), 1992-2018. For each panel, we show age-adjusted mortality rates by five mutually exclusive race-ethnicity categories: non-Hispanic White, non-Hispanic Black, non-Hispanic Asian Pacific Islander, non-Hispanic American Indian/Alaskan Natives, and Hispanic.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from The Impact of Improved Treatments on Survival of Adult US Leukemia Patients: 1990 - 2018
Supplementary Figure 1: Trends in Mortality by Leukemia Subtypes and Race Ethnicity. Total US 1992-2018. Results are shown for mortality trends for CML (panel A), ALL (panel B), and CLL (panel C), 1992-2018. For each panel, we show age-adjusted mortality rates by five mutually exclusive race-ethnicity categories: non-Hispanic White, non-Hispanic Black, non-Hispanic Asian Pacific Islander, non-Hispanic American Indian/Alaskan Natives, and Hispanic.
- Open Access
- 1 August 2024
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2024 (65) , 162-167
Real-world lessons: combining cancer registry and retail pharmacy data for oral cancer drugs
Background: Recent cancer care advances have introduced new oral therapies, and yet population registries lack detailed treatment data, hampering investigations into therapy uptake, adherence, and outcomes. Objective: This study aimed to assess the representativeness and completeness of linking Surveillance, Epidemiology, and End Results (SEER) cancer registry data with data from two major retail pharmacy chains, collectively covering a large segment of the US market. Methods: A deterministic data linkage between 11 SEER cancer registries and retail pharmacy data (excluding mail order fills) was conducted for individuals diagnosed with selected cancers from 2013 to 2017, with follow-up through 2019. Descriptive characteristics of the linked and unlinked populations were examined. In a selected subcohort of older women (aged ≥65) with first and only primary breast cancer who had Medicare Part D claims for tamoxifen, we further validated the linkage using Medicare Part D event data as the reference standard. Results: Among 758 068 eligible individuals, only 6.4% were linked to CVS/Walgreens data; the linkage percentage varied by age, sex, race, ethnicity, registry, and cancer type. Within the subcohort of 5963 older women with breast cancer and a claim for tamoxifen in Part D data, 25% were identified as tamoxifen users in retail pharmacy data. Out of these 1490 women, 749 (50.3%) had complete longitudinal tamoxifen dispensing information from retail pharmacy data. Conclusion: Retail pharmacy data show promise in identifying oral anticancer treatments, enhancing SEER registry efforts, but they require further validation. We propose an evaluation framework, sharing insights and potential use cases for this resource.
- 1 August 2024
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2024 (65) , 162-167
Open AccessReal-world lessons: combining cancer registry and retail pharmacy data for oral cancer drugs
Background: Recent cancer care advances have introduced new oral therapies, and yet population registries lack detailed treatment data, hampering investigations into therapy uptake, adherence, and outcomes. Objective: This study aimed to assess the representativeness and completeness of linking Surveillance, Epidemiology, and End Results (SEER) cancer registry data with data from two major retail pharmacy chains, collectively covering a large segment of the US market. Methods: A deterministic data linkage between 11 SEER cancer registries and retail pharmacy data (excluding mail order fills) was conducted for individuals diagnosed with selected cancers from 2013 to 2017, with follow-up through 2019. Descriptive characteristics of the linked and unlinked populations were examined. In a selected subcohort of older women (aged ≥65) with first and only primary breast cancer who had Medicare Part D claims for tamoxifen, we further validated the linkage using Medicare Part D event data as the reference standard. Results: Among 758 068 eligible individuals, only 6.4% were linked to CVS/Walgreens data; the linkage percentage varied by age, sex, race, ethnicity, registry, and cancer type. Within the subcohort of 5963 older women with breast cancer and a claim for tamoxifen in Part D data, 25% were identified as tamoxifen users in retail pharmacy data. Out of these 1490 women, 749 (50.3%) had complete longitudinal tamoxifen dispensing information from retail pharmacy data. Conclusion: Retail pharmacy data show promise in identifying oral anticancer treatments, enhancing SEER registry efforts, but they require further validation. We propose an evaluation framework, sharing insights and potential use cases for this resource.
- Open Access
- 17 May 2024
- Published by American Association for Cancer Research (AACR)
Data from The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018
Introduction:Molecularly targeted therapies such as tyrosine kinase inhibitors (TKI) are effective treatments for B-cell receptor (BCR)-ABL–bearing leukemias. We evaluated the impact of TKIs on historical chronic myeloid leukemia (CML) mortality trends compared with acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).Methods:Because mortality trends reflect combined effects of leukemia incidence and survival, we also evaluated the contribution of incidence and survival trends to mortality trends by subtypes. We used data from 13 U.S. (SEER) registries (1992–2017) among U.S. adults. We utilized histology codes to identify cases of CML, ALL, and CLL and death certificate data to calculate mortality. We used Joinpoint to characterize incidence (1992–2017) and mortality (1992–2018) trends by subtype and diagnosis year.Results:For CML, mortality rates started declining in 1998 at an average rate of 12% annually. Imatinib was approved by the FDA for treating CML and ALL in 2001, leading to clear benefits for patients with CML. Five-year CML survival increased dramatically over time, especially between 1996 to 2011, 2.3% per year on average. ALL incidence increased 1.5% annually from 1992 to 2017. ALL mortality decreased 0.6% annually during 1992 to 2012 and then stopped declining. CLL incidence fluctuated during 1992 to 2017 while mortality decreased 1.1% annually during 1992 to 2011 and at a faster rate of 3.6% per year from 2011. Five-year survival increased 0.7% per year on average during 1992 to 2016.Conclusions:Survival benefit from TKIs and other novel therapies for treating leukemia subtypes has been demonstrated in clinical trials.Impact:Our study highlights the impact of molecularly targeted therapies at the population level.
- 17 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018
Introduction:Molecularly targeted therapies such as tyrosine kinase inhibitors (TKI) are effective treatments for B-cell receptor (BCR)-ABL–bearing leukemias. We evaluated the impact of TKIs on historical chronic myeloid leukemia (CML) mortality trends compared with acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).Methods:Because mortality trends reflect combined effects of leukemia incidence and survival, we also evaluated the contribution of incidence and survival trends to mortality trends by subtypes. We used data from 13 U.S. (SEER) registries (1992–2017) among U.S. adults. We utilized histology codes to identify cases of CML, ALL, and CLL and death certificate data to calculate mortality. We used Joinpoint to characterize incidence (1992–2017) and mortality (1992–2018) trends by subtype and diagnosis year.Results:For CML, mortality rates started declining in 1998 at an average rate of 12% annually. Imatinib was approved by the FDA for treating CML and ALL in 2001, leading to clear benefits for patients with CML. Five-year CML survival increased dramatically over time, especially between 1996 to 2011, 2.3% per year on average. ALL incidence increased 1.5% annually from 1992 to 2017. ALL mortality decreased 0.6% annually during 1992 to 2012 and then stopped declining. CLL incidence fluctuated during 1992 to 2017 while mortality decreased 1.1% annually during 1992 to 2011 and at a faster rate of 3.6% per year from 2011. Five-year survival increased 0.7% per year on average during 1992 to 2016.Conclusions:Survival benefit from TKIs and other novel therapies for treating leukemia subtypes has been demonstrated in clinical trials.Impact:Our study highlights the impact of molecularly targeted therapies at the population level.